BioLife Solutions Balance Sheet Health
Financial Health criteria checks 5/6
BioLife Solutions has a total shareholder equity of $325.5M and total debt of $20.1M, which brings its debt-to-equity ratio to 6.2%. Its total assets and total liabilities are $381.7M and $56.2M respectively.
Key information
6.2%
Debt to equity ratio
US$20.05m
Debt
| Interest coverage ratio | n/a |
| Cash | US$34.19m |
| Equity | US$325.46m |
| Total liabilities | US$56.19m |
| Total assets | US$381.65m |
Recent financial health updates
Is BioLife Solutions (NASDAQ:BLFS) Weighed On By Its Debt Load?
Jan 24
Is BioLife Solutions (NASDAQ:BLFS) Using Debt Sensibly?
Oct 25BioLife Solutions (NASDAQ:BLFS) Has Debt But No Earnings; Should You Worry?
Jun 20Does BioLife Solutions (NASDAQ:BLFS) Have A Healthy Balance Sheet?
Mar 12Is BioLife Solutions (NASDAQ:BLFS) Weighed On By Its Debt Load?
Aug 11Recent updates
Is BioLife Solutions (NASDAQ:BLFS) Weighed On By Its Debt Load?
Jan 24BioLife Solutions, Inc.'s (NASDAQ:BLFS) Shares Climb 27% But Its Business Is Yet to Catch Up
Dec 15Is It Too Late To Consider Buying BioLife Solutions, Inc. (NASDAQ:BLFS)?
Nov 30Analysts Have Lowered Expectations For BioLife Solutions, Inc. (NASDAQ:BLFS) After Its Latest Results
Nov 15Is BioLife Solutions (NASDAQ:BLFS) Using Debt Sensibly?
Oct 25Is There An Opportunity With BioLife Solutions, Inc.'s (NASDAQ:BLFS) 20% Undervaluation?
Sep 14Why BioLife Solutions, Inc. (NASDAQ:BLFS) Could Be Worth Watching
Aug 30Investors Appear Satisfied With BioLife Solutions, Inc.'s (NASDAQ:BLFS) Prospects As Shares Rocket 28%
Aug 14BioLife Solutions (NASDAQ:BLFS) Has Debt But No Earnings; Should You Worry?
Jun 20A Look At The Fair Value Of BioLife Solutions, Inc. (NASDAQ:BLFS)
Jun 05Revenues Not Telling The Story For BioLife Solutions, Inc. (NASDAQ:BLFS) After Shares Rise 25%
May 14Broker Revenue Forecasts For BioLife Solutions, Inc. (NASDAQ:BLFS) Are Surging Higher
May 13Should You Investigate BioLife Solutions, Inc. (NASDAQ:BLFS) At US$19.54?
May 11Does BioLife Solutions (NASDAQ:BLFS) Have A Healthy Balance Sheet?
Mar 12BioLife Solutions, Inc.'s (NASDAQ:BLFS) Intrinsic Value Is Potentially 64% Above Its Share Price
Feb 19BioLife Solutions, Inc.'s (NASDAQ:BLFS) Share Price Matching Investor Opinion
Dec 19Downgrade: Here's How Analysts See BioLife Solutions, Inc. (NASDAQ:BLFS) Performing In The Near Term
Aug 17Is BioLife Solutions (NASDAQ:BLFS) Weighed On By Its Debt Load?
Aug 11Health Check: How Prudently Does BioLife Solutions (NASDAQ:BLFS) Use Debt?
May 06Should You Think About Buying BioLife Solutions, Inc. (NASDAQ:BLFS) Now?
Feb 22Health Check: How Prudently Does BioLife Solutions (NASDAQ:BLFS) Use Debt?
Jan 10Is There An Opportunity With BioLife Solutions, Inc.'s (NASDAQ:BLFS) 20% Undervaluation?
Dec 10Financial Position Analysis
Short Term Liabilities: BLFS's short term assets ($89.4M) exceed its short term liabilities ($32.2M).
Long Term Liabilities: BLFS's short term assets ($89.4M) exceed its long term liabilities ($24.0M).
Debt to Equity History and Analysis
Debt Level: BLFS has more cash than its total debt.
Reducing Debt: BLFS's debt to equity ratio has increased from 0% to 6.2% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable BLFS has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: BLFS is unprofitable but has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by 34.7% per year.
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/30 00:50 |
| End of Day Share Price | 2025/01/30 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
BioLife Solutions, Inc. is covered by 20 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Robert Wasserman | Benchmark Company |
| George Zavoico | B. Riley Securities, Inc. |
| Matthew Hewitt | Craig-Hallum Capital Group LLC |